Background: The Apgar score has been shown to be predictive of neonatal mortality in clinical and population studies, but has not been used for international comparisons. We examined population-level distributions in Apgar scores and associations with neonatal mortality in Europe. Methods: Aggregate data on the 5 minute Apgar score for live births and neonatal mortality rates from countries participating in the Euro-Peristat project in 2004 and 2010 were analysed. Country level associations between the Apgar score and neonatal mortality were assessed using the Spearman rank correlation coefficient. Results: Twenty-three countries or regions provided data on Apgar at 5 minutes, covering 2 183 472 live births. Scores <7 ranged from 0.3% to 2.4% across countries in 2004 and 2010 and were correlated over time (q = 0.88, P < 0.01). There were large differences in healthy baby scores: scores of 10 ranged from 8.8% to 92.7% whereas scores of 9 or 10 ranged from 72.9% to 96.8%. Countries more likely to score 10 s, as opposed to 9 s, for healthy babies had lower proportions of Apgar <7 (q = À0.43, P = 0.04). Neonatal mortality rates were weakly correlated with Apgar score <7 (q = À0.06, P = 0.61), but differences over time in these two indicators were correlated (q =0.56, P = 0.02). Conclusions: Large variations in the distribution of Apgar scores likely due to national scoring practices make the Apgar score an unsuitable indicator for benchmarking newborn health across countries. However, country-level trends over time in the Apgar score may reflect real changes and merit further investigation.
Since its introduction in 1952, the Apgar score has been used worldwide for the rapid and standardised assessment of neonates after delivery to determine the need for prompt resuscitative intervention.
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The Apgar score consists of five clinical signs which are each given a score of 0, 1, or 2 (Table S1 ). The overall Apgar score is the sum of these components and is defined as reassuring for a score of 7-10, moderately abnormal for a score of 4-6, and low for a score of 0-3. 3 The score is reported at 1 and 5 minutes after birth for all neonates, and subsequently at five-minute intervals until 20 minutes after birth for neonates with a non-reassuring score.
Over half a century since the Apgar score became integrated in routine clinical practice, it remains a standardised, effective, and convenient tool for neonatal assessment. [4] [5] [6] Although the Apgar score was never intended for the prediction of mortality or long-term disability, its utility beyond triage for immediate resuscitation is of significant interest. A low Apgar score at 1 minute can often be the result of a transient depression in the component parameters and has not been shown to be associated with clinical outcomes. 7 A low or moderately abnormal 5 minute Apgar score is, however, of greater predictive value, as evidenced by its correlation with neonatal mortality in large population and clinical studies. [5] [6] [7] [8] [9] [10] A non-reassuring 5 minute Apgar score has also been shown to be predictive of infant mortality. 8, 10, 11 Furthermore, large national registry studies with long-term follow up indicate an association of a 5 minute Apgar score less than 7 with neurological and developmental disabilities later in life, such as cerebral palsy, 9,10 epilepsy, 10 mental retardation, 10, 12 and lower academic achievement in secondary school. 13 Created for the assessment of term neonates, the physiological applicability of Apgar scores in preterm births is questioned since immaturity itself results in lower scores in the absence of neonatal distress. 14 However, population studies suggest that low Apgar scores are equally prognostic of mortality in preterm neonates. 8, 11, 15 The aforementioned studies suggest that, despite significant advances in perinatal care and neonatology since the Apgar score was introduced, it remains not only a relevant tool in the clinical management of neonates, but is also associated with mortality and morbidity at the population level. An analysis of population level trends in Apgar scores may therefore potentially serve as an internationally comparative indicator reflecting the burden of mortality and morbidity. While neonatal mortality is a key indicator of newborn health, its low incidence -under 2 per 1000 live births in many countries in Europe and under 3 per 1000 live births in the majority of European countries 16 -may reduce its usefulness for monitoring outcomes, in particular for sub-populations with a fewer number of births. The Apgar score is routinely collected by many European national health systems and could add to the tool kit for evaluating obstetrical and early neonatal quality of care. To our knowledge estimates of national aggregate Apgar scores have not previously been tested towards such an application. We examined population level rates and trends in Apgar scores to determine if they relate to neonatal mortality in European cross-country comparisons. Evidence suggests that there is significant interobserver variability in the 5 minute Apgar score, [17] [18] [19] [20] possibly due to its subjective components. Therefore, we also tested for differences between countries in the distribution of extreme and intermediate Apgar scores, to determine if norms vary nationally.
Methods
Data for this study were collected by the Euro-Peristat project which is an EU-funded network of clinicians, statisticians, and researchers from EU Member States, Norway, Iceland, and Switzerland. Scientific Committee members in each participating country are responsible for the data collection of 10 core and 20 recommended indicators essential for the surveillance of perinatal health. We used data collected on births in 2004 and 2010, published as part of the European Perinatal Health Reports. 21, 22 Full details of the EuroPeristat indicators are available on the Euro-Peristat website.
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The Euro-Peristat indicators are compiled from aggregated data provided from routine data sources. 23, 24 In most countries, perinatal health data were held in vital statistics, civil registers, and medical birth registers but data also came from nationally representative surveys of births in Cyprus and in France. Data were required to be population-based and should cover the whole country, but if countries could not provide information at the national-level, regional data were also accepted. For example, data for Belgium were provided separately from the regions of Brussels, Wallonia and Flanders, and data from the United Kingdom were provided separately by the UK's constituent countries: England and Wales combined, Northern Ireland, and Scotland. Finally, some countries could not provide data for the years requested, and data from the most recent year available were accepted. Data were collected on all births and deaths at or after 22 weeks; the 22-week gestational age threshold is recommended by Euro-Peristat for the collection of all data on births in Europe. 24 Gestational age was defined as the best obstetric estimate. When gestational age was missing, we asked countries to include births if birth weight was 500 grams or more. We used data from two indicators: the distribution of the 5 minute Apgar score and the neonatal mortality rate. We calculated percentages of live births with an Apgar score <4, 4-6 7-10. The neonatal mortality rate is defined as the number of neonatal deaths (day 0 through 27) after live birth and expressed per 1000 live births. Indicators from 2004 and 2010 were used.
For this ecological study, the unit of inference was the country. We first described the distributions of Apgar at 5 minutes across countries and examined the association of low Apgar scores across the two time periods to assess consistency and changes over time. We then correlated the proportions of low Apgar scores (<7), and very high Apgar scores of 9 or 10 across countries in order to assess whether coding practices for healthy infants affected the classification of high risk infants. To measure differences in coding practices we computed the proportion of neonates with a score of 10 among those with scores of 9 or 10 to measure the tendency to score more highly, independent of the Apgar score distribution overall. To investigate the association with neonatal mortality, we correlated low scores with neonatal mortality in 2004 and 2010, and studied temporal trends by assessing correlations between rate differences in the Apgar score and neonatal mortality between 2004 and 2010.
Spearman's non-parametric correlation was used for all analyses. While the focus was on low Apgar scores <7, we also assessed other clinically meaningful cut-offs: <4, representing the most critically abnormal scores and <9, representing anything besides completely healthy babies. To take into consideration differences in country population size, we integrated data on annual volume of births into graphical presentations to illustrate how countries with small numbers of annual births might affect the observed associations. However, we did not weight for country size as the country was our observation. Weighting by population size would effectively change the inference away from the ecological towards a study of the total population of the included countries. We also carried out sensitivity analyses by removing countries with low population sizes.
There were less than 3% missing data on the Apgar score in participating countries in 2004 and 2010. Exceptions included Finland (missing 19% in 2004 and 15% in 2010) and Wales (missing 22% in 2004 and 8% in 2010). For Finland, most children missing data at 5 minute had Apgar scores at 1 minute, since 5 minute scores may remain unrecorded if the 1 minute scores are high. For these births, we assigned the mean value at 5 minute corresponding to 1 minute Apgar scores as observed in the sample with non-missing values. Other missing data were excluded from the analyses. All analyses were performed using Stata, V.14.0 SE (Stata Corporation, College Station, Texas, USA).
Results
Twenty-three countries or regions covering a total of 2 192 632 live births provided data on Apgar scores in 2010, of which 6550 or 0.3% had scores under 4 with a range from 0.1% to 0.7% and a further 17 468 or 0.8% between 4 and 6, with a range from 0.2% to 1.7% ( Table 1 ). The percent of all Apgar scores <7 across countries ranged between 0.3-2.4%. Overall 93.2% of reported live births received Apgar scores of 9 or 10 with a range from 72.9% to 96.8%. Within this group there were large variations in the scoring of 9s vs. 10s. For example, in France 92.7% of the scores were 10 and only 3.9% were 9, whereas in Scotland 18.7% of scores were 10 and 76.3% were 9. Certain countries were outliers across the range of scores, most notably Estonia, Iceland, and Latvia. Apgar score distributions for 2004 are presented in Table S2 .
Apgar scores <7 in 2010 were highly correlated with scores <7 in 2004, as shown in Figure 1 (q = 0.88, P < 0.01). Scores of 10 ranged from 4% to 88% of total scores 9 and 10. Countries that were more likely to assign 10 had a lower prevalence of Apgar scores <7 in 2010 (Spearman's rho = À0.43, P = 0.04, 23 countries). A negative correlation was observed in 2004, but it was not statistically significant (Spearman's rho = À0.38, P = 0.10, 20 countries).
Neonatal mortality rates across countries were not associated with the proportion of abnormal Apgar scores <7 for both study years investigated ( Table S3 .
In countries with data on Apgar scores and neonatal mortality in both 2004 and 2010, the average decrease in neonatal mortality was 23% (an average rate difference of À0.77 per 1000), whereas Apgar scores <7 increased slightly by 2.8% (a rate difference of 0.14). Rate differences in the Apgar score <7 between these two periods were positively correlated with mortality rate differences ( Figure 3) . In sensitivity analyses removing the two smallest countries (Malta and Luxembourg) the estimation of the correlation coefficient remained positive, but the significance level declined (q=0.44, P = 0.09, 16 countries). The difference in the neonatal mortality rate was similarly correlated with rate differences in the proportions of Apgar scores <4 (q = 0.46, P = 0.06, N = 18) and <9 (q = 0.51, P = 0.03, 18 countries).
Comment

Principal findings
There were wide variations in the prevalence of newborns with low 5 minute Apgar score <7 across European countries, but our results suggest that some of this variability reflects heterogeneity in clinical scoring practices as opposed to true differences in biomedical outcomes. While there was no correlation between neonatal mortality rates and low Apgar scores in both years included in this study, changes at the country-level in proportions of newborns with low Apgar scores over time were associated with changes in neonatal mortality rates.
Strengths and limitations
This investigation had several strengths. We included data covering a broad geographical area representative of all regions of Europe. Data were collected for the same years using consistent data sources within countries. In addition, common data collection protocols and definitions of indicators (i.e. Apgar score and neonatal mortality rate) were employed. The use of aggregate data was a limitation of the study as it Region of Belgium; note data from Brussels includes women delivering in maternity units in Brussels and includes some women transferred into hospitals from outside the region. prevented the ability to explore medical and social covariates of interest or allow for more detailed statistical analyses within subgroups, for instance, assessing mortality rates by individual 5 minute Apgar scores or analysing Apgar scores by gestational age week. We were not able to identify cause-specific mortality which may be linked to the Apgar score, such as asphyxia or deaths due to very preterm birth. Another potential limitation was differences in data sources between countries which could lead to differences in data quality or other parameters.
Comparison with other studies and interpretation
The range of European 5 minute Apgar scores <7 identified in this study is consistent with those from other developed countries for which national data are available. In Australia, approximately 0.9% of all scores were less than 7 during 2004-09, however, the rates were higher than the national average among indigenous populations (1.4%) and babies delivered in public hospitals (1.1%). 25 In the United States, the overall proportion of scores less than 7 was 1.9% in 2012, however, the percentage was notably higher for Black babies (3.2%).
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Unlike our findings, prior clinical research as well as population based studies using routinely collected data found strong associations between neonatal mortality and low Apgar scores. [6] [7] [8] [9] [10] [11] 27 However, our study differed from these previous analyses in that it used cross-national ecological correlations of low Apgar scores and neonatal mortality rates. We hypothesise that some of the observed variation in Apgar scores reflect country-specific variations in scoring practices which may be a result of clinical training or convention. To investigate the effect of coding, we examined the more frequent use of a score of 10 as opposed to 9 for healthy babies (coded 9 or 10), which we considered to primarily reflect scoring practices because of the very large differences observed across countries in the attribution of the scores 10 vs. 9. The fact that a higher proportion of 10s was correlated with low scores suggests that scoring differences for healthy babies may cause a shift across the whole distribution and less stringent application of the score to high risk babies. Some of the variation in the prevalence of 9 vs. 10 scores could also reflect real differences between countries; one Canadian study found higher risk of developmental vulnerability at 5 years of age among the 82% of babies with an Apgar score of 9 vs. the 6% with an Apgar score of 10. 28 However, our study illustrates that findings such as these must be translated with caution into other contexts, as we observed a range from 9% to 93% in scores of 10. The subjective nature of the Apgar score's various components as well as differences in clinical conditions, such as resuscitation, have previously been posited as reasons for inter-observer variability within countries.
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We could not take into consideration the effect of early neonatal interventions such as resuscitation and mechanical ventilation. The uncertainty of assigning Apgar scores in these circumstances could be one of the reasons for the differences in cross-national scoring. 'Expanded' or 'combined' Apgar scores with additional objective clinical components describing resuscitative measures have been proposed which may be better suited to modern healthcare settings. 4, 14, 29, 30 These have been shown in some instances to be superior in predicting outcomes as compared to the traditional Apgar score. 31 While these results call into question the external validity of the Apgar score for comparing the prevalence of high risk newborns at birth across countries, we found correlations between changes in Apgar scores and neonatal mortality over time. By using rate differences, country specific errors in measurement of indicators would be minimised. These results suggest that this indicator could provide useful information about national trends in newborn health, however, they should be replicated using more complete time series data and more countries. 
Implications for future research, policy, and practice
This study suggests that comparisons of Apgar scores across countries should not be undertaken without first assessing the external validity of this indicator. Despite the existence of a common definition and established guidelines for assigning Apgar scores, its translation into practice was highly heterogeneous across countries. Although there is wide agreement on the <7 threshold for defining low scores, this threshold would potentially select different subsets of children depending on a specific country's coding practices. Higher thresholds may be even more vulnerable to variations in scoring practices, as shown by large differences in the prevalence of newborns with Apgar scores of 9 vs. 10. However, integrating more information on delivery, cause-specific mortality, gestational age, as well as early neonatal interventions could make it possible to improve post hoc standardisation of the scoring system across different contexts by, for instance, comparing Apgar scores among term infants or taking into consideration the proportion of infants who are ventilated.
More generally, this study highlights the difficulty of conducting valid cross-national comparisons of health and the importance of examining the external validity of indicators used for these comparisons. This may be true for other health indicators which presume a common definition and shows the need for research to validate indicators used to benchmark health and care internationally.
Conclusion
Internationally comparative perinatal health indicators make it possible to assess differences in practices and outcomes and to assess interventions towards the creation of best practices. However, while the Apgar score is available in many routine databases and may have good internal validity, as shown by many previous studies linking it to perinatal and child health outcomes, our analysis suggests that the external validity in cross-national comparisons is limited. These results do not support the use of the Apgar score to benchmark newborn health across countries without more work to standardise coding and reporting; however, monitoring trends over time in Apgar scores could provide additional information about newborn health and quality of obstetrical and early neonatal care.
Further research, integrating additional information on pregnancy and newborn characteristics and interventions would be useful to confirm these findings.
